What genetic changes are associated with Shiga toxin–producing Escherichia coli hemolytic uremic syndrome (STEC‑HUS)?

Genetic changes in STEC‑HUS

• Bold, high‑risk genotypes: stx2a (alone or with stx2c or stx1a), plus the LEE locus (eae/tir), best predict HUS, morbidity, and renal sequelae. 1, 2, 3

• Core Shiga toxin determinants

  • stx2a subtype (± stx2c; ± stx1a) strongly associated with progression to HUS, severe disease, and worse renal outcomes versus stx1-only strains 1, 2, 3.
  • O157:H7 strains almost universally carry stx2 and eae (intimin), a high‑risk genomic combination for HUS 1.

• Adhesion/LEE island and effectors

  • eae (intimin) and tir (its receptor) co-occur with HUS and severe phenotypes; expanded T3SS effector repertoires are overrepresented in HUS isolates 3, 2.

• Serotype/clade context (markers of risk, not causal themselves)

  • O157:H7, especially clade 8, is enriched among HUS cases and linked to severe renal sequelae; high‑risk non‑O157 serogroups (e.g., O26, O121) often harbor stx2a ± plasmid virulence genes (ehxA, etpD) 4, 3, 5.
  • Emerging O26 ST29 lineages with stx2a and specific plasmid cargos are prominent in pediatric HUS in Europe 5.

• Accessory/plasmid and genomic features enriched in HUS isolates

  • Hemolysin (ehxA), cytolethal distending toxin, additional adhesins, and multiple secretion system effectors are overrepresented in HUS‑associated STEC; numerous outer‑membrane, regulator, and phage genes track with HUS on pangenome analyses 2, 3.
  • Recent GWAS signals: co‑presence of ygiW with group_5720, or pfkA with fieF, may further stratify HUS risk (hypothesis‑generating) 6.

• Complement system genetics (host vs pathogen)

  • In STEC‑HUS, alternative pathway activation is prominent; however, pathogen genetic drivers dominate risk (stx2a/eae), while host complement risk polymorphisms show limited, inconsistent contribution; rare overlap with aHUS genetics can modify course in select patients 7, 8.

• Practical, outcome‑focused testing algorithm (to reduce morbidity/mortality)

  • Immediately test stools for Shiga toxins (EIA/PCR) and culture for O157; if STEC detected, request stx subtyping and eae/tir status; flag stx2a±eae as high‑risk → aggressive hydration, avoid antibiotics/antimotility, close monitoring for HUS and AKI 1.
  • Public health labs should confirm serotype and perform molecular typing to identify high‑risk lineages (e.g., O157 clade 8; O26 ST29 with stx2a) that portend higher HUS and renal sequelae risk 1, 4, 5.

• Pitfalls/caveats

  • Do not assume low risk with non‑O157: stx2a‑positive non‑O157 (O26/O121/O145) cause HUS; stx profile trumps serogroup for clinical risk 1, 2, 3.
  • Mixed stx profiles (stx1a+stx2a or stx2a+stx2c) are high risk; stx1‑only strains are lower risk but not benign—monitor if eae-positive 6, 2.
  • Genomic backgrounds are diverse; no single phylogeny cleanly separates HUS vs non‑HUS—focus management on stx2a and LEE markers 2, 3.